Efficacy of Livojith in patients with Moderate Non-Alcoholic Fatty Liver Disease (NAFLD)

A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Hepatoprotective Efficacy of Livojith in Patients with Moderate Non-Alcoholic Fatty Liver Disease (NAFLD) - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/11/098167

Enrollment

Registered

2025-11-27

Start date

Unknown

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Adults aged 30 to 60 years with a confirmed diagnosis of NAFLD either by history or NAFLD Score between -1.455 and 0.675.

Exclusion criteria

Exclusion criteria: History of significant alcohol consumption, presence of other chronic liver diseases (e.g., viral hepatitis, autoimmune hepatitis), or ongoing use of hepatoprotective agents or lipid-lowering medications.

Design outcomes

Primary

Measure	Time frame
Change in Non alcoholic fatty liver fibrosis score at Week 4 and week 8.Timepoint: 2nd,4th 6th,and 8th wk	—

Secondary

Measure	Time frame
Change in Chronic Liver Disease Questionnaire for NAFLD/NASH at baseline and week 8.Timepoint: Baseline and 8th week;Safety assessment through LFT, RFT and CBC, adverse events categorised according to CTCAE version 4.03 where study specific AE is defined with a severity of grade 3 or more and(or) that leads to discontinuation of the study drugTimepoint: 2nd,4th 6th,and 8th wk	—

Countries

India

Contacts

Public ContactDr Somit Kumar

The Arya Vaidya Pharmacy (Coimbatore) Limited

cso@avpresearch.org9003856200

Outcome results